Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
Burkhard Otremba,1 Carsten Hielscher,2 Volker Petersen,3 Christian Petrik4 1Oncological Practice Oldenburg/Delmenhorst, Oldenburg, Germany; 2Gynecology Competence Center Stralsund, Stralsund, Germany; 3Practice for Hematology and Oncology, Heidenheim, Germany; 4Pfizer Inc, Berlin, Germany Backgrou...
Main Authors: | Otremba B, Hielscher C, Petersen V, Petrik C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/home-administration-of-filgrastim-nivestimtrade-in-primary-prophylaxis-peer-reviewed-article-PPA |
Similar Items
-
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
by: Innocenti R, et al.
Published: (2018-12-01) -
Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01) -
Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
by: Sevinç A, et al.
Published: (2018-01-01) -
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01) -
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
by: Roberto Hegg, et al.